BONE SOLUTIONS, INC. (BSI) is a Dallas, Texas based, orthobiologics technology company.
OsteoCrete® is a Next Generation magnesium Bio-material with a unique combination of characteristics, making it ideal for a wide range of orthopaedic applications as a bone void filler.
BSI’s first step to achieving that vision is to introduce its revolutionary new product, OsteoCreteTM, which is a unique material used to complement hardware needed in repairs of complex fractures and in joint replacement procedures.
OsteoCreteTM has the most powerful profile of performance characteristics in its product category, therefore its primary benefit is to increase success rates of notoriously difficult orthopedic surgeries that are performed as a result of trauma and joint replacements.
BSI intends to establish its stable of patents of Magnesium-based technologies to obtain increased success rates in a multitude of orthopedic applications.
OUR VISION to provide orthopedic surgeons a means to improve clinical outcomes in a number of complex procedures, while lowering costs.
OsteoCrete® is a Next Generation magnesium Bio-material with a unique combination of characteristics, making it ideal for a wide range of orthopaedic applications as a bone void filler. OsteoCrete is osteoconductive, biocompatible and resorbs over time while supporting bone formation.
OsteoCreteTM is the first and only bone graft substitute that possesses the powerful combination of bone void filler properties. The key to this revolutionary blend of properties is OsteoCreteTM is the only Magnesium-based bone graft substitute on the market. The most active chemical is Magnesium Oxide, with portions of Monopotassium Phosphate, Monosodium Phosphate, and Tricalcium Phosphate. Hence, OsteoCreteTM has no polymers, which are the most frequent causes of rejection of acrylic-based bone cements, and this is the reason OsteoCreteTM has extremely low rates of inflammatory side effects. Moreover, unlike hydroxiapatite-based bone void fillers, OsteoCreteTM is appropriately absorbed by the body, making the surgical area visible to X-ray on follow up after the procedure.
Magnesium is critical for bone health and development. It has been found that the role of magnesium and its’ characteristics has a much broader effect than previously thought. The most attractive physical characteristics of Mg are its high specific strength and an elastic modulus that closely resembles human bone. The properties are of great importance as high mechanical strength reduces the amount of implant material needed for a given applied load and reducing the elastic modulus mismatch alleviates stress-shielding effects between bone and the implant material.
Magnesium is also an essential mineral for human metabolism and its deficiency has been linked to various pathological conditions. The human body contains about 24 grams of Mg. It is the second most common intracellular ion and serves as a cofactor for more than 300 enzymatic reactions ranging from muscle contraction to neuronal control. Most of the Mg in the body (53%) is stored in bone, in an apatite inorganic matrix subject to regulated release which stimulates the hormone calcitonin, helping preserve and develop bone structure by working with Vitamin D and calcium.
OsteoCrete’s patented, proprietary formula includes critical components needed to help maximize the process of bone health and development.
The OsteoCrete product portfolio will enhance surgical outcomes because of its’ unique physical properties. In the near future, Bone Solutions Inc., will continue to pursue new FDA approvals in many additional key orthopaedic markets including Spine, Cranial Maxillofacial, Trauma and Dental that globally account for over $44.0 billion in annual sales, thus addressing bone void filler markets in excess of $4.0 billion globally.
Bone Solutions Inc. products will improve upon existing filler products with its, bio-absorbable and superior physical attributes to repair non-load bearing injuries more efficiently and cost-effectively.
OsteoCrete has already received FDA 510(k) clearance as a bone void filler for long bone and pelvis and is anticipated to enter the marketplace in 2016.
FOUNDER AND CHAIRMAN
CHIEF OPERATING OFFICER, DIRECTOR
CHIEF FINANCIAL OFFICER